おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Biocytogen
company
About
Biocytogen is a biopharmaceutical company that provides integrated solutions for antibody drug development.
- 1001 - 5000
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- ¥543M
- Industries
- Biotechnology,Health Care,Medical Device,Therapeutics
- Founded date
- Nov 1, 2008
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
Biocytogen is a biopharmaceutical company that provides biomedical communities with integrated solutions for antibody drug development. Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM Mouse), and in vivo/in vitro preclinical validation studies, using gene editing technologies and a state-of-the-art animal facility. Biocytogen works with the world's leading pharmaceutical and biotechnology companies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
¥1.51B
Biocytogen has raised a total of
¥1.51B
in funding over 2 rounds. Their latest funding was raised on
Sep 15, 2020 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 15, 2020 | Series D | ¥0.97B | 1 | — | — | Detail |
| Aug 8, 2019 | Series D | ¥543M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Biocytogen is funded by 1 investors.
China Life Healthcare Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
